June 23, 2020 / 12:11 PM / 19 days ago

BRIEF-Tyme-18 Demonstrates Anti-Cancer Effect In New Preclinical Data Presented At AACR 2020

June 23 (Reuters) - Tyme Technologies Inc:

* TYME-18 DEMONSTRATES ANTI-CANCER EFFECT IN NEW PRECLINICAL DATA PRESENTED AT AACR 2020

* TYME TECHNOLOGIES- PRECLINICAL ANIMAL STUDIES SHOWED TYME-18’S POTENTIAL TO DRAMATICALLY SHRINK AND/OR RESOLVE TUMORS

* TYME TECHNOLOGIES - TYME-18 TREATMENT RESULTED IN A 91.6% (11/12) COMPLETE RESOLUTION OF ESTABLISHED TUMORS WITHIN TWO WEEKS

* TYME TECHNOLOGIES INC - PRECLINICAL STUDIES ARE ONGOING WITH A GOAL OF IDENTIFYING AN IND-ENABLING PROGRAM

* TYME TECHNOLOGIES INC - TYME-18 DID NOT SHOW LOCAL OR SYSTEMIC TOXICITIES IN TREATED MICE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below